Kalbe Farma Tbk PT
IDX:KLBF

Watchlist Manager
Kalbe Farma Tbk PT Logo
Kalbe Farma Tbk PT
IDX:KLBF
Watchlist
Price: 1 135 IDR 3.18% Market Closed
Market Cap: 53.2T IDR

EV/EBIT
Enterprise Value to EBIT

12.3
Current
18.5
Median
15.8
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
12.3
=
Enterprise Value
48.7T IDR
/
EBIT
4T IDR
Market Cap EV/EBIT
ID
Kalbe Farma Tbk PT
IDX:KLBF
52.4T IDR 12.3
US
Eli Lilly and Co
NYSE:LLY
761.5B USD 46.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 17 702.3
US
Johnson & Johnson
NYSE:JNJ
400.1B USD 17.5
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 15.4
CH
Roche Holding AG
SIX:ROG
231.8B CHF 13.4
UK
AstraZeneca PLC
LSE:AZN
174.2B GBP 193.6
CH
Novartis AG
SIX:NOVN
198.4B CHF 14.6
US
Merck & Co Inc
NYSE:MRK
225.2B USD 10.5
IE
Endo International PLC
LSE:0Y5F
167.6B USD 670.8
US
Pfizer Inc
NYSE:PFE
141.5B USD 12.1
EBIT Growth EV/EBIT to Growth
ID
Kalbe Farma Tbk PT
IDX:KLBF
Average EV/EBIT: 1 700.8
12.3
11%
1.1
US
Eli Lilly and Co
NYSE:LLY
46.2
33%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
17.5
12%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
15.4
16%
1
CH
Roche Holding AG
SIX:ROG
13.4
9%
1.5
UK
AstraZeneca PLC
LSE:AZN
193.6
21%
9.2
CH
Novartis AG
SIX:NOVN
14.6
8%
1.8
US
Merck & Co Inc
NYSE:MRK
10.5
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
670.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
12.1
10%
1.2

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
11.7
2-Years Forward
EV/EBIT
10.7
3-Years Forward
EV/EBIT
9.8